## Thure Filskov Overvad

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1483263/publications.pdf

Version: 2024-02-01

46 papers

1,434 citations

430843 18 h-index 330122 37 g-index

49 all docs

49 docs citations

times ranked

49

2542 citing authors

#	Article	IF	CITATIONS
1	Validation of the Khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy. Blood Advances, 2022, 6, 2967-2976.	5 <b>.</b> 2	23
2	Risk of Cerebrovascular Events in Intracerebral Hemorrhage Survivors With Atrial Fibrillation: A Nationwide Cohort Study. Stroke, 2022, 53, 2559-2568.	2.0	5
3	Thromboembolism and bleeding complications in anticoagulated patients with atrial fibrillation and native aortic or mitral valvular heart disease: a descriptive nationwide cohort study. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, f101-f110.	3.0	14
4	Should We Reintroduce Previous Venous Thromboembolism Into Decision-Making for Anticoagulation in Atrial Fibrillation?. American Journal of Medicine, 2021, 134, 67-75.e5.	1.5	O
5	Management of Cancer-Associated Venous Thrombosis: A Nationwide Survey among Danish Oncologists. TH Open, 2021, 05, e188-e194.	1.4	2
6	Increasing Incidence and Declining Mortality After Cancer-Associated Venous Thromboembolism: A Nationwide Cohort Study. American Journal of Medicine, 2021, 134, 868-876.e5.	1.5	15
7	Association of Cycling With All-Cause and Cardiovascular Disease Mortality Among Persons With Diabetes. JAMA Internal Medicine, 2021, 181, 1196.	5.1	16
8	Effectiveness and Safety of NOAC Versus Warfarin in Patients With Atrial Fibrillation and Aortic Stenosis. Journal of the American Heart Association, 2021, 10, e022628.	3.7	5
9	Correspondence: Current opinion of the ESC Working Group on Cardiovascular Pharmacotherapy and ESC Council on Stroke. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 265-266.	3.0	1
10	Predictors of Not Initiating Anticoagulation After Incident Venous Thromboembolism: A Danish Nationwide Cohort Study. American Journal of Medicine, 2020, 133, 463-472.e5.	1.5	5
11	DEVELOPMENT OF SEX-STRATIFIED PREDICTION SCORES FOR RECURRENT VENOUS THROMBOEMBOLISM: A DANISH NATIONWIDE COHORT STUDY. Journal of the American College of Cardiology, 2020, 75, 2210.	2.8	O
12	Cancer-associated venous thromboembolism and the non-vitamin K antagonist oral anticoagulants: a review of clinical outcomes and patient perspectives. Expert Review of Cardiovascular Therapy, 2020, 18, 791-800.	1.5	6
13	Development of Sex-Stratified Prediction Models for Recurrent Venous Thromboembolism: A Danish Nationwide Cohort Study. Thrombosis and Haemostasis, 2020, 120, 805-814.	3.4	13
14	Female Sex as a Risk Modifier for Stroke Risk in Atrial Fibrillation: Using CHA2DS2-VASc versus CHA2DS2-VA for Stroke Risk Stratification in Atrial Fibrillation: A Note of Caution. Thrombosis and Haemostasis, 2020, 120, 894-898.	3.4	26
15	Thromboembolic and bleeding outcomes in patients with atrial fibrillation and valvular heart disease: A descriptive nationwide cohort study. International Journal of Clinical Practice, 2020, 74, e13589.	1.7	6
16	Incidence and prognostic factors for recurrence of intracerebral hemorrhage in patients with and without atrial fibrillation: A cohort study. Thrombosis Research, 2020, 191, 1-8.	1.7	9
17	Albuminuria and Risk of Cardiovascular Events and Mortality in a General Population of Patients with Type 2 Diabetes Without Cardiovascular Disease: A Danish Cohort Study. American Journal of Medicine, 2020, 133, e269-e279.	1.5	17
18	Thromboembolic Risk in Nonanticoagulated Patients With Atrial Fibrillation and Valvular Heart Disease. JACC: Clinical Electrophysiology, 2020, 6, 1672-1682.	3.2	1

#	Article	IF	CITATIONS
19	Sex differences in risk of incident venous thromboembolism in heart failure patients. Clinical Research in Cardiology, 2019, 108, 101-109.	3.3	15
20	Glycemic Status and Thromboembolic Risk in Patients With Atrial Fibrillation and Type 2 Diabetes Mellitus. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007030.	4.8	39
21	USING THE CHA2DS2-VASC SCORE TO PREDICT ISCHEMIC STROKE IN PATIENTS WITH INTRACEREBRAL HEMORRHAGE: A NATIONWIDE COHORT STUDY. Journal of the American College of Cardiology, 2019, 73, 503.	2.8	О
22	Risk Stratification for Ischemic Cerebrovascular Events and Mortality among Intracerebral Hemorrhage Patients with and without Atrial Fibrillation: A Nationwide Cohort Study. Cerebrovascular Diseases, 2019, 48, 236-243.	1.7	6
23	Stroke Risk Stratification: CHA2DS2-VA or CHA2DS2-VASc?. Heart Lung and Circulation, 2019, 28, e14-e15.	0.4	10
24	Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation. Circulation, 2018, 137, 832-840.	1.6	158
25	Risk of stroke and bleeding in patients with heart failure and chronic kidney disease: a nationwide cohort study. ESC Heart Failure, 2018, 5, 319-326.	3.1	11
26	Response by Overvad et al to Letter Regarding Article, "Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation: Should We Use a CHA 2 DS 2 -VA Score Rather Than CHA 2 DS 2 -VASc?― Circulation, 2018, 138, 443-444.	1.6	0
27	Risk of Recurrent Venous Thromboembolism: A Danish Nationwide Cohort Study. American Journal of Medicine, 2018, 131, 1067-1074.e4.	1.5	55
28	Type 1 versus type 2 diabetes and thromboembolic risk in patients with atrial fibrillation: A Danish nationwide cohort study. International Journal of Cardiology, 2018, 268, 137-142.	1.7	22
29	Treatment thresholds for stroke prevention in atrial fibrillation: observations on the CHA <sub>2</sub> DS <sub>2</sub> -VASc score. European Heart Journal - Cardiovascular Pharmacotherapy, 2017, 3, 37-41.	3.0	32
30	Recent Diabetes and AtrialÂFibrillation ReportÂDiverges From Pre-Existing Evidence. Journal of the American College of Cardiology, 2016, 67, 2318-2319.	2.8	0
31	Drug-Eluting Balloons in the Treatment of Coronary De Novo Lesions: A Comprehensive Review. Cardiology and Therapy, 2016, 5, 133-160.	2.6	32
32	Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: A nationwide cohort study. Scientific Reports, 2016, 6, 27410.	3.3	67
33	Left atrial size and risk of stroke in patients in sinus rhythm. Thrombosis and Haemostasis, 2016, 116, 206-219.	3.4	51
34	Smoking, atrial fibrillation, and ischemic stroke. Current Opinion in Cardiology, 2015, 30, 512-517.	1.8	13
35	Comparison of Atrial Fibrillation Guidelines. Journal of General Internal Medicine, 2015, 30, 1404-1404.	2.6	О
36	Duration of Diabetes Mellitus and Risk of Thromboembolism and Bleeding in Atrial Fibrillation. Stroke, 2015, 46, 2168-2174.	2.0	72

#	Article	IF	Citations
37	Female sex as a risk factor for thromboembolism and death in patients with incident atrial fibrillation. Thrombosis and Haemostasis, 2014, 112, 789-795.	3.4	16
38	Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 955-967.	0.5	124
39	Non-invasive risk scores for prediction of type 2 diabetes (EPIC-InterAct): a validation of existing models. Lancet Diabetes and Endocrinology,the, 2014, 2, 19-29.	11.4	132
40	The Impact of Smoking on Thromboembolism and Mortality in Patients With Incident Atrial Fibrillation. Chest, 2014, 145, 559-566.	0.8	54
41	Body Mass Index and Adverse Events in Patients with Incident Atrial Fibrillation. American Journal of Medicine, 2013, 126, 640.e9-640.e17.	1.5	91
42	Risk of Stroke or Systemic Embolism in Atrial Fibrillation Patients Treated With Warfarin. Stroke, 2013, 44, 1329-1336.	2.0	95
43	Balancing bleeding and thrombotic risk with new oral anticoagulants in patients with atrial fibrillation. Expert Review of Cardiovascular Therapy, 2013, 11, 1619-1629.	1.5	15
44	Alcohol intake and prognosis of atrial fibrillation. Heart, 2013, 99, 1093-1099.	2.9	51
45	Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study. Breast Cancer Research, 2012, 14, R76.	5.0	94
46	Prevention of Venous Thromboembolism with New Oral Anticoagulants versus Standard Pharmacological Treatment in Acute Medically Ill Patients. Drugs, 2012, 72, 1755-1764.	10.9	15